look news india
The rising trend in shares of Hamps Bio continues. On Friday, the company’s shares closed on the upper circuit, taking its share price to Rs 81.86. The company’s IPO came last month in December and after its spectacular listing, the shares attracted the attention of investors.
IPO and listing performance
- IPO launch:
- This IPO was open for retail investors on 13 December 2024.
- It was available for investment till 17 December 2024.
- The IPO received an overwhelming response and was subscribed more than 1000 times.
- Stock Exchange Listing:
- On December 20, 2024, shares of Hamps Bio were listed at Rs 96.
- This listing came with a premium of 90%.
- The share price had reached Rs 101.70 on the day of listing itself.
- Decline and Revival:
- After the initial rally, the shares witnessed a decline and touched Rs 75.
- The stock performed well in the new year and is now trading 60% above its IPO price.
Company’s financial position: stable and profitable
Hamps Bio has strong financials and is profitable.
- Net Profit:
- FY 2023: Rs 36 lakh.
- FY 2024: Rs 50 lakh.
- Revenue:
- FY 2023: Rs 5.58 crore.
- FY 2024: Rs 6.48 crore.
Company Business: Pharma and Nutritional Supplements
Hamps Bio operates in the marketing and distribution of pharmaceuticals and nutritional supplements.
- Product Range:
- Tablets, syrups, capsules.
- Oil, Gel, Powder etc.
- Segment:
- Supply of products used in medicines and nutritional supplements.
Expectations for investors
- Hamps Bio has shown mixed performance since its IPO, but its rally in the new year has investors excited.
- As it stands, the stock is trading 60% higher than its IPO price, making it a strong option for long-term investment.
